dostarlimab subcutaneous / GSK, Alteogen - LARVOL DELTA

Alteogen said on Tuesday that it signed an exclusive licensing agreement with GSK subsidiary Tesaro to develop and commercialize a subcutaneous formulation of the immuno-oncology drug dostarlimab using its hyaluronidase ALT-B4, powered by the Hybrozyme platform. (Pulse by Maeil Business News Korea) - "Under the terms of the agreement, Alteogen will receive an upfront payment of $20 million. The company is also eligible to receive up to $265 million in milestone payments tied to development, regulatory approval and sales achievements. The total deal value, including the upfront payment and milestones, amounts to up to $285 million. Alteogen will additionally receive royalties based on product sales after commercialization. The company will be responsible for supplying ALT-B4 for both clinical and commercial use."

Licensing / partnership • Oncology